Device Explantation
Removal of an implanted device, whether planned (the end of a time-limited study) or unplanned (infection, hardware failure, participant withdrawal, migration, or a sponsor ending support). Explant is a core part of the surgical and ethical plan, not an afterthought. Chronically implanted arrays become tethered by fibrous tissue and neovascularization, so removal can be more difficult and hazardous than insertion, and a device or fragments may be intentionally left in place when extraction would pose greater risk.
Explant also raises a distinct ethical burden when it ends a benefit the participant has come to rely on, such as restored communication or control. Whether, when, and at whose cost a device is removed or maintained after a study is a central post-trial-obligation question that trial designs increasingly must address in advance rather than improvise at the end.
A percutaneous pedestal develops a persistent skin infection two years after implant. The array itself records well, but the surgeons must weigh explanting a fibrotically anchored device — with its own hemorrhage and cortical-injury risk — against continued antibiotics, knowing removal ends the communication the participant now depends on.
Explant is rarely a clean reversal: it can be riskier than implant and can end a benefit the participant relies on.